Cue Biopharma (CUE) Liabilities and Shareholders Equity (2017 - 2025)

Cue Biopharma has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $42.2 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $42.2 million, up 31.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $136.8 million (down 21.04% YoY), and the FY2025 annual result was $42.2 million, up 31.13% from the prior year.
• Liabilities and Shareholders Equity came in at $42.2 million for Q4 2025 at Cue Biopharma, up from $31.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $91.3 million in Q4 2022 to a low of $22.3 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $71.0 million (2023), against an average of $64.0 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 46.29% in 2021 and tumbled 58.75% in 2025, its largest moves.
• Cue Biopharma's Liabilities and Shareholders Equity stood at $83.4 million in 2021, then gained by 9.45% to $91.3 million in 2022, then tumbled by 32.59% to $61.5 million in 2023, then plunged by 47.68% to $32.2 million in 2024, then soared by 31.13% to $42.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $42.2 million (Q4 2025), $31.6 million (Q3 2025), and $40.7 million (Q2 2025), per Business Quant data.